The surge comes as the country grapples with a growing obesity crisis, ranking third globally in terms of the number of obese individuals
The formula is proven with 15 years clinical research in humans, is safe, and free from synthetic additives
Unlike earlier GLP-1 receptor agonists, retatrutide is a triple agonist : GLP-1 receptor agonist suppresses appetite, slows gastric emptying, improves insulin sensitivity GIP receptor agonist enhances insulin release, amplifies GLP-1 effects Glucagon receptor agonist stimulates energy expenditure, fat metabolism, and potentially impacts lipid handling Clinical trials so far have shown remarkable weight loss (up to 24% in some studies) and strong metabolic improvements, including effects on lipids like LDL cholesterol
Retatrutide is the newest weight loss medication that acts as a triple agonist at GLP-1, GIP, and glucagon receptors